糖基因在髓性白血病耐药性中特征性改变

Characteristic alteration of glycogenes in multidrug resistance of myelogenous leukemia

目的通过研究糖基因在髓性白血病中的差异表达,明确这些糖基因与白血病耐药的相关性,从而为预测和诊断髓性白血病耐药性,寻求逆转药物提供新策略和靶点。方法采用real-time PCR技术筛选髓性白血病细胞及其耐药细胞株中差异表达的糖基因,筛选出两组细胞差异表达3倍以上的糖基因,初步探索糖基因在髓性白血病耐药性中的特征性改变;采用流式细胞仪分析髓性白血病耐药细胞株与多种FITC标记植物凝集素的结合能力,表征比较细胞膜表面糖链的特征。结果 12个糖基因在NB4和NB4/ADR细胞株中表达具有显著的差异;高表达的糖基因与FITC标记植物凝集素的结合能力增强。结论髓性白血病细胞及其耐药细胞株中糖基因、细胞膜表面糖链特征均有显著差异,这些特征性改变与白血病多药耐药具有相关性。

Objective To investigate the differential expression of glycogenes in drug-resistant NB4/ADR cells and parental NB4 line, and clarify the correlation of glycogenes and multidrug resistance of myelogenous leukemia, so as to further predict and diagnose myelogenous leukemia multidrug resistance, and provide a new therapeutic strategy and target point of myelogenous leukemia. Methods Using real-time PCR for quantification of glycogenes, we compared the differential expression （i. e. , 3-fold and/or higher） of glycogenes in drug-resistant NB4/ADR cells with that in parental NB4 line to explore the characteristic alteration of glycogenes in muhidrug resistance of myelog- enous leukemia. Using FITC-lectin binding for glycan profiling, we compared the glycan profiling and N-glycan composition of drug-resistant NB4/ADR cells with those of parental NB4 line. Results 12 genes （ i. e. , 3-fold and/or higher） were differentially expressed in the two leukemic cell lines, NB4 and NB4/ADR. High expressions of gly（.ogene were corresponding with high fluorescence intensity of lectins in both cell lines. Conclusion The expression of glycogenes and glycan profiling are different in NB4/ADR cells, as compared with those in NB4 cells. These characteristic alterations are associated with muhidrug resistance in myelogenous leukemia.